FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Takanori Matsui

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Living Beings

Rats

Physiology

Up-Regulation

Co-author Network

Publications

TOP 3
Y Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Growth and VEGF Expression in MCF-7 Breast Cancer Cells by Suppressing AGEs Receptor Expression via AMP-activated Protein Kinase.
Ayako Ojima; Masayoshi Takeuchi; Kei Fukami; Yuji Ishibashi; Sayaka Maeda; Takanori Matsui; Yuri Nishino; Sho-ichi Yamagishi
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Yuji Ishibashi; Takanori Matsui; Kei-ichiro Nakamura; Keisuke Ohta; Seiya Okuda; Masayoshi Takeuchi; Ryuichiro Tanoue; Katsuhiko Asanuma; Kei Fukami; Sho-ichi Yamagishi
PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Takanori Matsui (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Y Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Growth and VEGF Expression in MCF-7 Breast Cancer Cells by Suppressing AGEs Receptor Expression via AMP-activated Protein Kinase.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2013;45(5):387-90.
2013: Ayako Ojima; Masayoshi Takeuchi; Kei Fukami; Yuji Ishibashi; Sayaka Maeda; Takanori Matsui; Yuri Nishino; Sho-ichi Yamagishi
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
The American journal of pathology 2013;182(1):132-41.
2013: Yuji Ishibashi; Takanori Matsui; Kei-ichiro Nakamura; Keisuke Ohta; Seiya Okuda; Masayoshi Takeuchi; Ryuichiro Tanoue; Katsuhiko Asanuma; Kei Fukami; Sho-ichi Yamagishi
PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation.
Microvascular research 2013;85():54-8.
2012: Y Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2012;44(12):891-5.
2012: Yuji Ishibashi; Sayaka Maeda; Takanori Matsui; Sae Nakashima; Yuri Nishino; Ayako Ojima; Sho-ichi Yamagishi
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A.
Microvascular research 2012;84(3):395-8.
2012: Yuji Ishibashi; Takanori Matsui; Kei-ichiro Nakamura; Keisuke Ohta; Masayoshi Takeuchi; Ryuichiro Tanoue; Seiji Ueda; Sho-ichi Yamagishi; Seiya Okuda
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.
Metabolism: clinical and experimental 2012;61(8):1067-72.
2012: Sho-ichi Yamagishi; So Ueda; Yuji Ishibashi; Sayaka Maeda; Takanori Matsui
Serum pigment epithelium-derived factor levels are independently associated with decreased number of circulating endothelial progenitor cells in healthy non-smokers.
International journal of cardiology 2012;158(2):310-2.
2012: A Ojima; Masayoshi Takeuchi; S Maeda; Takanori Matsui; Sho-ichi Yamagishi
Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2012;44(7):501-5.
2012: Sho-ichi Yamagishi; Seiji Ueda; Kei Fukami; Sayaka Maeda; Takanori Matsui; Seiya Okuda
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Biochimica et biophysica acta 2012;1820(5):663-71.
2012: Yuji Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
Pharmacological research : the official journal of the Italian Pharmacological Society 2012;65(3):297-302.
2012: Nobuhiro Tahara; Masayoshi Takeuchi; Sho-ichi Yamagishi; Norihiro Kodama; Takanori Matsui; Minori Mizoguchi; Yoshikazu Nitta; Tsutomu Imaizumi
Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects.
Cardiovascular therapeutics 2012;30(1):42-8.
2011: Sayaka Maeda; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation.
International journal of cardiology 2011;152(3):408-10.
2011: Y Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(10):731-4.
2011: Sho-ichi Yamagishi; Takanori Matsui
Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe?
Pharmacological research : the official journal of the Italian Pharmacological Society 2011;64(3):187-94.
2011: Yuji Ishibashi; Takanori Matsui; Yuri Nishino; Masayoshi Takeuchi; Sho-ichi Yamagishi
Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level.
Metabolism: clinical and experimental 2011;60(9):1271-7.
2011: Y Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(9):619-24.
2011: Yuji Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP.
Clinical and experimental medicine 2011;11(2):131-5.
2011: Takanori Matsui; Yuri Nishino; Masayoshi Takeuchi; Sho-ichi Yamagishi
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
Pharmacological research : the official journal of the Italian Pharmacological Society 2011;63(5):383-8.
2011: Takanori Matsui; Yuri Nishino; Sayaka Maeda; Masayoshi Takeuchi; Sho-ichi Yamagishi
Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells.
Microvascular research 2011;81(3):269-73.
2011: Sayaka Maeda; Takanori Matsui; Masayoshi Takeuchi; Yumiko Yoshida; Ryoji Yamakawa; Kei Fukami; Sho-ichi Yamagishi
Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Pharmacological research : the official journal of the Italian Pharmacological Society 2011;63(3):241-8.
2011: Sho-ichi Yamagishi; Takanori Matsui
Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy.
Current pharmaceutical biotechnology 2011;12(3):362-8.
2010: Sho-ichi Yamagishi; Takanori Matsui; So Ueda; Masayoshi Takeuchi
Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats.
International journal of cardiology 2010;144(2):283-5.
2010: Yuichiro Ide; Takanori Matsui; Yuji Ishibashi; Masayoshi Takeuchi; Sho-ichi Yamagishi
Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.
Microvascular research 2010;80(2):227-32.
2010: Takanori Matsui; Sho-ichi Yamagishi; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda
Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Biochemical and biophysical research communications 2010;398(2):326-30.
2010: Sho-ichi Yamagishi; Takanori Matsui
Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).
Current drug targets 2010;11(7):875-81.
2010: Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity.
Biochemical and biophysical research communications 2010;396(2):566-70.
2010: Sho-ichi Yamagishi; Takanori Matsui
Anti-atherothrombogenic properties of PEDF.
Current molecular medicine 2010;10(3):284-91.
2010: Sho-ichi Yamagishi; Takanori Matsui
Advanced glycation end products, oxidative stress and diabetic nephropathy.
Oxidative medicine and cellular longevity 2010;3(2):101-8.
2010: Sho-ichi Yamagishi; Takanori Matsui; Hisashi Adachi; Masayoshi Takeuchi
Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population.
Pharmacological research : the official journal of the Italian Pharmacological Society 2010;61(2):103-7.
2010: Yuji Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression.
Biochemical and biophysical research communications 2010;391(3):1405-8.
2010: Sho-ichi Yamagishi; Takanori Matsui
Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.
Frontiers in bioscience (Elite edition) 2010;2():1184-95.
2010: Sho-ichi Yamagishi; Takanori Matsui; T Kawaguchi; M Sata
Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders.
Current medicinal chemistry 2010;17(19):1995-2000.
2010: Takanori Matsui; Sho-ichi Yamagishi; Seiji Ueda; Kei Fukami; Seiya Okuda
Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro.
Protein and peptide letters 2010;17(1):74-7.
2010: Takanori Matsui; Sho-ichi Yamagishi; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.
Pharmacological research : the official journal of the Italian Pharmacological Society 2010;61(1):34-9.
2009: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Yuko Jinnouchi; Kei Fukami; Tsutomu Imaizumi; Ryoji Yamakawa
Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy.
Diabetes/metabolism research and reviews 2009;25(7):678-86.
2009: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(3):174-8.
2009: Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Kazuo Nakamura; Mika Enomoto; Ako Fukami; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Tsutomu Imaizumi
Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population.
Clinical cardiology 2009;32(9):E29-32.
2009: Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Mika Enomoto; Ako Fukami; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Shin-ichiro Ueda; Tsutomu Imaizumi
Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects.
Clinical cardiology 2009;32(9):E12-5.
2009: Takanori Matsui; Sho-ichi Yamagishi; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Biochemical and biophysical research communications 2009;385(2):269-72.
2009: Toshiko Fujimura; Sho-ichi Yamagishi; Seiji Ueda; Kei Fukami; Ryo Shibata; Yuriko Matsumoto; Yusuke Kaida; Ayako Hayashida; Kiyomi Koike; Takanori Matsui; Kei-ichiro Nakamura; Seiya Okuda
Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(5):1397-406.
2009: Kazuo Nakamura; Hisashi Adachi; Takanori Matsui; Yayoi Kurita; Masayoshi Takeuchi; Sho-ichi Yamagishi
Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.
Metabolism: clinical and experimental 2009;58(3):421-5.
2009: Sho-ichi Yamagishi; Takanori Matsui; Katsuhiko Takenaka; Kazuo Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue
Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs).
Diabetes/metabolism research and reviews 2009;25(3):266-71.
2009: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; K Takenaka
Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats.
Clinical and experimental medicine 2009;9(1):73-6.
2009: Sho-ichi Yamagishi; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Current drug metabolism 2009;10(2):159-63.
2009: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders.
Current pharmaceutical design 2009;15(9):1027-33.
2009: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Hiroyoshi Inoue
Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes.
Diabetes/metabolism research and reviews 2009;25(1):52-6.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes.
Medical hypotheses 2008;71(6):876-8.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; So Ueda; Yoshihiro Noda; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.
Current drug targets 2008;9(11):1025-9.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
Medical hypotheses 2008;71(5):749-51.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(9):640-4.
2008: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Masayoshi Takeuchi; Hironori Koga; Takato Ueno; Michio Sata
Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(9):620-5.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
Medical hypotheses 2008;71(2):259-61.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Expert opinion on investigational drugs 2008;17(7):983-96.
2008: Takafumi Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Takato Ueno; Masayoshi Takeuchi; Michio Sata
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.
The Journal of international medical research 2008;36(2):237-43.
2008: Katsuhiko Takenaka; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Yuko Jinnouchi; Yumiko Yoshida; Shin-ichiro Ueda; Yoshio Katsuki; Yousuke Katsuda; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes.
Atherosclerosis 2008;197(1):25-33.
2008: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Yayoi Kurita-Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue; Tsutomu Imaizumi
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Diabetes/metabolism research and reviews 2008;24(2):109-14.
2008: Sho-ichi Yamagishi; Seiji Ueda; Kazuo Nakamura; Takanori Matsui; Seiya Okuda
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Current pharmaceutical design 2008;14(25):2613-8.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue
Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
Protein and peptide letters 2008;15(8):850-3.
2008: Sho-ichi Yamagishi; Seiji Ueda; Takanori Matsui; Kazuo Nakamura; Seiya Okuda
Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Current pharmaceutical design 2008;14(10):962-8.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; So Ueda; Yoshihiro Noda; Tsutomu Imaizumi
Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
Cardiovascular therapeutics 2008;26(1):50-8.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Yoshihiro Noda; Tsutomu Imaizumi
Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Current pharmaceutical design 2008;14(5):487-95.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Current medicinal chemistry 2008;15(2):172-7.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi; Seiji Ueda; Seiya Okuda; Tsutomu Imaizumi
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
Ophthalmic research 2008;40(1):10-5.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda; Tsutomu Imaizumi
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Microvascular research 2008;75(1):130-4.
2007: Sho-ichi Yamagishi; R Abe; Yuko Jinnouchi; Takanori Matsui; Tsutomu Imaizumi; Hiroyoshi Inoue
Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo.
The Journal of international medical research 2007;35(6):896-9.
2007: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
The Journal of international medical research 2007;35(6):886-91.
2007: Sho-ichi Yamagishi; Hisashi Adachi; Masayoshi Takeuchi; Mika Enomoto; Kumiko Furuki; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(11):845-8.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Current drug targets 2007;8(10):1138-43.
2007: Yuko Jinnouchi; Sho-ichi Yamagishi; Takanori Matsui; Katsuhiko Takenaka; Yumiko Yoshida; Kazuo Nakamura; Shin-ichiro Ueda; Tsutomu Imaizumi
Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
Brain research 2007;1167():92-100.
2007: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Koichi Yoshimura; Ryoji Yamakawa
Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy.
The British journal of ophthalmology 2007;91(9):1133-4.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Current molecular medicine 2007;7(5):463-9.
2007: Takanori Matsui; Sho-ichi Yamagishi; Seiji Ueda; Kazuo Nakamura; Tsutomu Imaizumi; Masayoshi Takeuchi; Hiroyoshi Inoue
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
The Journal of international medical research 2007;35(4):482-9.
2007: Sho-ichi Yamagishi; Takanori Matsui; Shin-Ichiro Ueda; Kazuo Nakamura; Tsutomu Imaizumi
Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes.
Cardiovascular & hematological agents in medicinal chemistry 2007;5(3):236-40.
2007: Yuichiro Higashimoto; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Masayoshi Takeuchi; Masato Noguchi; Hiroyoshi Inoue
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes.
Microvascular research 2007;74(1):65-9.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Akira Sato; Tsutomu Imaizumi
Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Diabetes/metabolism research and reviews 2007;23(5):368-71.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Takanori Matsui; Takafumi Yoshida; Katsuhiko Takenaka; Yuko Jinnouchi; Yumiko Yoshida; Shin-ichiro Ueda; Hisashi Adachi; Tsutomu Imaizumi
Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation.
The American journal of pathology 2007;170(6):2159-70.
2007: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Koichi Yoshimura; Ryoji Yamakawa
Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis.
The British journal of ophthalmology 2007;91(6):737-8.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Takafumi Yoshida; Takanori Matsui; Tsutomu Imaizumi; Hiroyoshi Inoue; Michio Sata
Hydrogen peroxide stimulates pigment epithelium-derived factor gene and protein expression in the human hepatocyte cell line OUMS-29.
The Journal of international medical research 2007;35(3):427-32.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Molecular medicine (Cambridge, Mass.) 2007;13(3-4):185-9.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Takafumi Yoshida; Masayoshi Takeuchi; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(3):233-5.
2007: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Koichi Yoshimura; Ryoji Yamakawa
Increased levels of pigment epithelium-derived factor in aqueous humor of patients with uveitis.
The British journal of ophthalmology 2007;91(2):149-50.
2007: Sho-ichi Yamagishi; Seiji Ueda; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Masayoshi Takeuchi; Seiya Okuda
Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties.
Protein and peptide letters 2007;14(8):832-5.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties.
Protein and peptide letters 2007;14(6):615-7.
2007: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi
Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells.
The Journal of international medical research 2007;35(1):107-12.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Hiroyoshi Inoue; Masayoshi Takeuchi
Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2007;69(3):666-8.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Hiroyoshi Inoue
A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2007;69(2):338-40.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Takafumi Yoshida; Masayoshi Takeuchi; Hiroyoshi Inoue; Yumiko Yoshida; Tsutomu Imaizumi
Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Ophthalmic research 2007;39(2):92-7.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
Medical hypotheses 2007;68(5):1096-8.
2006: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Masayoshi Takeuchi; H Koga; Takato Ueno; Michio Sata
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.
Diabetologia 2006;49(12):3094-9.
2006: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
The Journal of international medical research 2006;34(6):671-5.
2006: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Hiroyoshi Inoue; Takato Ueno; Michio Sata
Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation.
Life sciences 2006;79(21):1981-7.
2006: Sho-ichi Yamagishi; Hisashi Adachi; Kazuo Nakamura; Takanori Matsui; Yuko Jinnouchi; Katsuhiko Takenaka; Masayoshi Takeuchi; Mika Enomoto; Kumiko Furuki; Asuka Hino; Yoshiyuki Shigeto; Tsutomu Imaizumi
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Metabolism: clinical and experimental 2006;55(9):1227-31.
2006: Sho-ichi Yamagishi; Seiji Kikuchi; Kazuo Nakamura; Takanori Matsui; T Makino; O Norisugi; Tadamichi Shimizu; Hiroyoshi Inoue; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2006;38(8):546-8.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Yosuke Inagaki; Katsuhiko Takenaka; Yuko Jinnouchi; Yumiko Yoshida; Tetsuro Matsuura; Isao Narama; Yoshihiro Motomiya; Masayoshi Takeuchi; Hiroyoshi Inoue; Akihiko Yoshimura; Richard Bucala; Tsutomu Imaizumi
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression.
The Journal of biological chemistry 2006;281(29):20213-20.
2006: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis.
Microvascular research 2006;72(1-2):86-90.
2006: Sho-ichi Yamagishi; Hisashi Adachi; Akio Abe; Takako Yashiro; Mika Enomoto; Kumiko Furuki; Asuka Hino; Yuko Jinnouchi; Katsuhiko Takenaka; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome.
The Journal of clinical endocrinology and metabolism 2006;91(6):2447-50.
2006: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Masayoshi Takeuchi; Takato Ueno; Michio Sata
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation.
FEBS letters 2006;580(11):2788-96.
2006: Sho-ichi Yamagishi; Seiji Kikuchi; Kazuo Nakamura; Takanori Matsui; Masayoshi Takeuchi; Hiroyoshi Inoue
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2006;2(3):265-9.
2006: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Takafumi Yoshida; Kyoko Shimizu; Yoshiaki Takegami; Tadamichi Shimizu; Hiroyoshi Inoue; Tsutomu Imaizumi
Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties.
Microvascular research 2006;71(3):222-6.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Current drug discovery technologies 2006;3(1):83-8.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Katsuhiko Takenaka; Yuko Jinnouchi; Tsutomu Imaizumi
Cardiovascular disease in diabetes.
Mini reviews in medicinal chemistry 2006;6(3):313-8.
2006: Katsuhiko Takenaka; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes.
Current neurovascular research 2006;3(1):73-7.
2006: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Atorvastatin and diabetic vascular complications.
Current pharmaceutical design 2006;12(12):1549-54.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Katsuhiko Takenaka; Takanori Matsui; Hiroyoshi Inoue
Pleiotropic effects of nifedipine on atherosclerosis.
Current pharmaceutical design 2006;12(12):1543-7.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Masayoshi Takeuchi
Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
Medical hypotheses 2006;66(2):273-5.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; T Sato; Masayoshi Takeuchi
Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Medical hypotheses 2006;66(4):844-6.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; T Sato; Masayoshi Takeuchi
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Medical hypotheses 2006;66(5):1019-21.
2006: Sho-ichi Yamagishi; Takanori Matsui; T Sato; Masayoshi Takeuchi
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Medical hypotheses 2006;66(3):609-11.
2005: Katsuhiko Takenaka; Sho-ichi Yamagishi; Yuko Jinnouchi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells.
Life sciences 2005;77(25):3231-41.
2005: Kazuo Nakamura; Sho-ichi Yamagishi; Yayoi Nakamura; Katsuhiko Takenaka; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
Microvascular research 2005;70(3):137-41.
2005: Sho-ichi Yamagishi; Masayoshi Takeuchi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Hiroyoshi Inoue
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.
FEBS letters 2005;579(20):4265-70.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Katsuhiko Takenaka; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B.
Microvascular research 2005;69(3):128-34.
2005: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue
Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy.
International journal of tissue reactions 2005;27(4):197-202.
2005: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi
Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
International journal of tissue reactions 2005;27(4):189-95.
2005: Sho-ichi Yamagishi; Takanori Matsui; Hiroyoshi Inoue
Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.
Drugs under experimental and clinical research 2005;31(5-6):227-32.
2005: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Seiji Kikuchi; Hiroyoshi Inoue
Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Drugs under experimental and clinical research 2005;31(5-6):215-9.
2005: Kazuo Nakamura; Sho-ichi Yamagishi; Takanori Matsui; Hiroyoshi Inoue
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Drugs under experimental and clinical research 2005;31(4):155-9.